Walgreens Boots Alliance — Q3 2024 Earnings Presentation
36 slides from Walgreens Boots Alliance's earnings presentation, Jun 27, 2024
Slide 1: Third Quarter Fiscal 2024 Results
Third Quarter Fiscal 2024 Results June 27th, 2024 © 2024 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 2: Safe Harbor and Non-GAAP
Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat
Slide 3: Foundational strengths and near-term priorities
Foundational strengths and near-term priorities Foundational strengths Near-term priorities • Trusting relationship with our customers • Navigate retail and pharmacy industry headwinds, and reconfigure businesses • Nationwide presence serving millions daily for future • Deep relationships with payor
Slide 4: Quarterly performance and outlook
Quarterly performance and outlook • 3Q operational results were below expectations • U.S. Retail Pharmacy performance impacted by challenging pharmacy industry trends and a worse- than-expected consumer environment • U.S. Healthcare delivered a second consecutive quarter of positive adjusted EBITDA1
Slide 5: Performance across business segments
Performance across business segments U.S. Retail Pharmacy • Comp scripts excluding immunizations1 +1.7% vs. 3Q23, maintaining YTD share in a weaker market Navigating external headwinds • Continued reimbursement pressures net of procurement savings weighed on profitability while delivering cost savin
Slide 6: WBA 3Q24 Financial Highlights
Reported Fx Constant Fx 3Q24 $ in millions (except EPS) B/(W) vs. 3Q23 B/(W) vs. 3Q231 Sales $36,351 + 2.6% + 2.5% Operating Income GAAP $111 + $588 Adjusted1 $613 (36.1)% (36.3)% WBA 3Q24 Net Earnings GAAP $344 + $225 Financial Adjusted1 $545 (36.6)% (36.5)% Highlights EPS GAAP $0.40 + $0.26 Adjust
Slide 7: WBA YTD24 Financial Highlights
Reported Fx Constant Fx YTD24 $ in millions (except EPS) B/(W) vs. YTD23 B/(W) vs. YTD231 Sales $110,111 + 6.2% + 5.6% Operating Income GAAP ($13,099) ($6,667) Adjusted1 $2,200 (31.0)% (31.5)% WBA YTD24 Net Earnings GAAP ($5,631) ($2,731) Financial Adjusted1 $2,152 (24.9)% (25.3)% Highlights EPS GAA
Slide 8: U.S. Retail Pharmacy Financials
B/(W) vs. 3Q24 B/(W) vs. 3Q23 YTD24 $ in millions YTD23 Sales $28,503 + 2.3% $86,308 + 4.4% Adj. gross profit1 $5,022 (6.7)% $16,086 (6.2)% U.S. Retail Adj. SG&A % of sales1 16.2% + 0.1%p 16.7% + 0.7%p Pharmacy Adj. operating income1 $501 (47.9)% $1,947 (37.9)% Financials Adj. operating margin1,2 1.
Slide 9: U.S. Pharmacy
3Q24 3Q23 YTD24 YTD23 3Q24 vs. 3Q23 | YTD24 vs. YTD23 Total Comparable1 Total Comparable1 Pharmacy sales + 4.4% + 5.7% + 7.7% + 9.1% Prescriptions + 0.5% + 1.6% + 1.0% + 1.9% Prescriptions ex. + 0.6% + 1.7% + 1.2% + 2.1% Immunizations U.S. Pharmacy • Comp pharmacy sales1 +5.7% due to brand inflation
Slide 10: U.S. Retail
3Q24 YTD24 3Q24 vs. 3Q23 | YTD24 vs. YTD23 Total retail sales (4.0)% (4.9)% Comparable retail sales1 (2.3)% (3.9)% U.S. Retail • Comp retail sales1 down 2.3%, primarily due to a challenging retail environment and continued channel shift, including: − (90) bps impact from lower health & wellness incl
Slide 11: International Financials
Constant Fx1 Constant Fx1 3Q24 YTD24 B/(W) vs. B/(W) vs. 3Q23 $ in millions YTD23 Sales $5,727 + 1.6% $17,581 + 3.0% Adj. gross profit1 $1,222 + 2.0% $3,720 + 4.0% International Adj. SG&A % of sales1 18.3% (0.8)%p 18.0% (1.1)%p Financials Adj. operating income1 $175 (16.6)% $562 (19.4)% Adj. operati
Slide 12: Boots UK Financials
3Q24 YTD24 3Q24 vs. 3Q23 | YTD24 vs. YTD23 (constant Fx) Pharmacy comp. sales1 + 5.8% + 2.7% Retail comp. sales1 + 6.0% + 7.1% Boots UK • Strong retail comp sales1 +6.0% with growth across all categories, on top of +13.4% Financials in the prior year ― Growth in Destination Health & Beauty, Flagship
Slide 13: U.S. Healthcare Financials
B/(W) vs. 3Q24 B/(W) vs. 3Q23 YTD24 $ in millions YTD23 Sales $2,125 + $150 $6,232 + $1,634 Adj. gross profit1 $203 + $89 $560 + $292 Adj. SG&A1 ($225) + $61 ($711) + $40 Adj. operating loss1 ($22) + $150 ($151) + $332 U.S. Healthcare Adj. EBITDA1 $23 + $136 $1 + $347 Financials • 3Q sales led by Vi
Slide 14: Cash Flow
B/(W) YTD24 $ in millions vs. YTD23 Operating cash flow ($314) ($1,532) Cash capital expenditure ($1,135) $497 Free cash flow1,2 ($1,063) ($1,179) Cash Flow • Operating cash flow negatively impacted by $785M in payments related to legal matters, $386M Boots Pension Plan Annuity premium contributions
Slide 15: Lowering FY24 adj. EPS guidance to $2.80 - $2.95
Lowering FY24 adj. EPS1 guidance to $2.80 - $2.95 • Reflects recent developments in U.S. Retail Pharmacy business: − Worse-than-expected consumer environment driving higher promotional activity, negatively impacting retail margin − Continuation of challenging pharmacy industry trends affecting margi
Slide 16: Strategic review: Near-term opportunities and actions
Strategic review: Near-term opportunities and actions • Retail pharmacy business is core to WBA and critical to the future of healthcare • U.S. Pharmacy: Focused on strengthening profitability − Aligning organization for enhanced go-to-market capabilities − Changing the dialogue with partners for be
Slide 17: Q&A
Q&A 1. Refer to safe harbor and non-GAAP disclosure on slide 2, © 2024 Walgreens Boots Alliance, Inc. All rights reserved. endnotes on slide XX, and reconciliations on slides XX-XX 17
Slide 18: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 19: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 20: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,
Slide 21: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR As Reported Twelve months ended May 31, 2024 Net loss (GAAP) $ (12,578) Post-ta
Slide 22: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa
Slide 23: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS (LOSS) TO ADJUSTED NET EARNINGS AND DILUTED NET EARNINGS (LOSS) PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended May 31
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET EARNINGS (LOSS) TO ADJUSTED NET EARNINGS AND DILUTED NET EARNINGS (LOSS) PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE
Slide 25: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Impairment of goodwill, intangibles and long-lived assets recognized in the nine months ended May 31, 2024 resulted from the interim goodwill impairment assessment for
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 15 Due to the anti-dilutive effect resulting from periods where the Company reports a net loss, the impact of potentially dilutive securities on the per share amounts ha
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2024 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 28,503 $ 5,7
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,866 $ 5,5
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2024 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 86,308 $ 17,5
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 82,648 $ 16,4
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income (loss) for U.S. Retail Pharmacy includes equity earnings in Cencora. As a result of the two-month reporting lag, operating income for the three and ni
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR U.S. HEALTHCARE SEGMENT Three months ended May 31, Nine months ended May 31, 2024 2023 2024 2023 Operating loss (GAAP
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN CENCORA Three months ended Nine months ended May 31, 2024 May 31, 2023 May 31, 2024 May 31, 2023 Equity earnings in Cencora (GAAP) $ 44
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2024 Three months ended May 31, 2023 (Loss) Earnings Earnings before before income Income tax income
Slide 35: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2024 2023 2024 2023 Net cash provided (used for) by operating activities (GAAP) $ 605 $
Slide 36: Sale-Leaseback Financial Information
Sale-Leaseback Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Sale-leaseback financial information Three months ended Nine months ended May 31, 2024 Change vs. 3Q23 May 31, 2024 Change vs. FY23 U.S. Retail Pharmacy Gain on sal
Walgreens Boots Alliance — Q3 2024 Earnings Presentation on 6ix